DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG: Natural-based Sweeteners - DOLCE core team announces membership changes in programme for natural-based sweeteners


 
DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG / Key word(s): Miscellaneous B.R.A.I.N. Biotechnology Research And Information Network AG: Natural-based Sweeteners - DOLCE core team announces membership changes in programme for natural-based sweeteners 30.08.2018 / 09:10 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Natural-based Sweeteners DOLCE core team announces membership changes in programme for natural-based sweeteners * Business options for non-exclusive members were reshaped by the DOLCE core team * CPGC member who had access to the fields "morning foods" and "snacks" left for company-internal strategic reasons * DOLCE programme is moving forward and open for new partnerships Zwingenberg, Potsdam (Germany) La Madeleine Cedex (France) August 30, 2018 The bioeconomy company BRAIN AG, the natural product specialist AnalytiCon Discovery GmbH and Roquette, a global leader in specialty food ingredients from plant-based raw materials - together the DOLCE core team - announce today, that a CPGC member (Consumer Product Goods Company) of the DOLCE partnership for natural-based sweetening solutions has left the program for company-internal strategic reasons. The company was a partner to the programme for the two food categories "morning foods" and "snacks". New industry partners are invited to join DOLCE, allowing them to test the natural-based sweetening solutions early in the development phase directly within their specific product matrixes for their own product portfolio. For non-exclusive members of the partnership the business model was reshaped to enable the new members an easier access to the programme. The goal of the DOLCE partnership is providing next generation natural-based sweetening solutions for healthier food and beverages. Since the launch of the programme in August 2016 significant product categories were selected. The core team is currently preparing new partnerships for available product categories and negotiations with potential members. Sergio Neves, Head of Nutrition and Health R&D at Roquette Group, says: "DOLCE is a great program. At the beginning of this year, we reached an important milestone by identifying and characterizing a number of natural-based sweet taste enhancers and high intensity sweeteners which we can share with members of the partnership." Martin Langer, EVP Corporate Development at BRAIN, says: "The DOLCE programme is moving forward with high business potential for all parties involved. We continue to invite further CPGCs to join our ongoing successful programme." Lutz Müller-Kuhrt, CEO of AnalytiCon Discovery states: "During the last two years we made good progress in the programme. We started with 50 natural sweetener candidates, now identified another 20, many of them new and already applied for patent by the team. We are happy to provide this collection of molecules to our DOLCE members and help them to reduce the sugar load in their products." For additional information on joining the DOLCE programme, please contact: Dr. Martin Langer, BRAIN AG, Executive Vice President Corporate Development, Tel.: +49-6251-9331-16, E-Mail: [email protected] About BRAIN B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) is one of Europe's leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by help of this "Toolbox of Nature" are successfully applied in the chemistry, the cosmetics and the food industries. BRAIN's business model is based on two pillars - BioScience and BioIndustrial. The BioScience comprises its frequently exclusive collaboration business with industrial partners. BioIndustrial comprises the development and commercialization of BRAIN's own products and active product components. Further information is available at www.brain-biotech.de/en. About AnalytiCon Discovery AnalytiCon Discovery GmbH is a global market leader in the area of compound libraries containing fully analyzed structures. Located on the Potsdam Biotech Campus, the company offers services for every stage of the supply chain for natural product-based (NP-based) substance discoveries and developments. Innovative technology concepts enable high-grade partnerships with globally operating companies from the pharmaceutical, food manufacturing and cosmetics industries. AnalytiCon Discovery enjoys access to around 15 percent of all natural compounds known worldwide, as well as to thousands of structures that have not yet been published. AnalytiCon Discovery has been a member of the BRAIN Group since 2013. Further information is available at www.ac-discovery.com. About Roquette: "Offering the best of Nature" Roquette is a global leader in plant-based ingredients and a pioneer of new vegetal proteins. In collaboration with its customers and partners, the Group addresses current and future societal challenges by unlocking the potential of Nature to offer the best ingredients for Food, Nutrition and Health markets. Each of these ingredients responds to unique and essential needs, and they enable healthier lifestyles. Thanks to a constant drive for innovation and a long-term vision, the Group is committed to improving the well-being of millions of people all over the world while taking care of resources and territories. Roquette currently operates in over 100 countries, has a turnover of around 3.2 billion euros and employs 8,300 people worldwide. Further information is available at www.roquette.com. BžRžAžIžN Biotechnology Research And Information Network AG Darmstädter Str. 34-36 64673 Zwingenberg, Germany www.brain-biotech.de AnalytiCon Discovery GmbH Hermannswerder Haus 17 14473 Potsdam, Germany www.ac-discovery.com Media Contact Thomas Deichmann Head of Public Relations Tel.: +49-(0)-6251-9331-72 [email protected] Corporate Develop. & IR Contact Dr. Martin Langer Executive Vice President Corporate Development Tel.: +49-(0)-6251-9331-16 Fax: +49-(0)-6251-9331-11 [email protected] Roquette 101 avenue de la République 59564 La Madeleine Cedex France www.roquette.com Media Contact Carole Petitjean Corporate Communications Tel: +33 3 21 63 36 00 [email protected] --------------------------------------------------------------------------- 30.08.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: B.R.A.I.N. Biotechnology Research And Information Network AG Darmstädter Straße 34-36 64673 Zwingenberg Germany Phone: +49 (0) 62 51 / 9331-0 Fax: +49 (0) 62 51 / 9331-11 E-mail: [email protected] Internet: www.brain-biotech.de ISIN: DE0005203947 WKN: 520394 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange End of News DGAP News Service --------------------------------------------------------------------------- 718179 30.08.2018


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 24,11 27,05 38,56 38,23 38,39 45,51 55,34
EBITDA1,2 -7,70 -6,55 -2,50 -3,88 -2,53 -1,31 -0,83
EBITDA-Marge3 -31,94 -24,21 -6,48 -10,15 -6,59 -2,88
EBIT1,4 -9,37 -9,57 -7,20 -8,23 -6,55 -5,65 -5,48
EBIT-Marge5 -38,86 -35,38 -18,67 -21,53 -17,06 -12,42 -9,90
Jahresüberschuss1 -9,40 -8,37 -11,12 -9,02 -4,68 -6,34 -8,11
Netto-Marge6 -38,99 -30,94 -28,84 -23,59 -12,19 -13,93 -14,66
Cashflow1,7 -5,80 -5,42 -3,38 -4,77 -3,10 -1,49 -4,22
Ergebnis je Aktie8 -0,58 -0,45 -0,61 -0,52 -0,25 -0,30 -0,38
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Baker Tilly

INVESTOR-INFORMATIONEN
©boersengefluester.de
BRAIN Biotech
WKN Kurs in € Einschätzung Börsenwert in Mio. €
520394 2,840 Halten 62,05
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
28,40 0,00 0,00 -6,17
KBV KCV KUV EV/EBITDA
2,85 - 1,12 -104,88
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,00 0,00 0,00 12.03.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
28.02.2024 28.05.2024 29.08.2024 17.01.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-20,98% -28,50% -22,40% -50,52%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu B.R.A.I.N. Biotechnology Research And Information Network AG  ISIN: DE0005203947 können Sie bei EQS abrufen


Biotechnologie , 520394 , BNN , XETR:BNN